Financial Results for the 2nd Quarter of the Year Ending March 31, 2013 <Supplement>

As of October 29, 2012

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma

Table of Contents

1 Summary of Financial Results for the 2nd Quarter of FY2012 Ending March 31, 2012 and Forecasts for FY2012

(Amounts less than ¥100 million are rounded down.)

1. Summary of Financial Results for the 2nd Quarter of FY2012

[Billion yen]

Net Sales	203.8	Y-on-Y	3.4	1.7 %
Pharmaceuticals	200.7	Y-on-Y	5.3	2.7 %
Other Businesses	3.0	Y-on-Y	(1.8)	(37.4 %)

In the pharmaceuticals segment, net sales were ¥200.7 billion, up 2.7%, or ¥5.3 billion, year-on-year.
Although there were the NHI drug price revisions implemented in April 2012 and the growing impact of generics, in domestic sales of ethical drugs, sales were expanded by Remicade, an anti-TNF α monoclonal antibody. In addition, Telavic, for the treatment of chronic hepatitis C, and other new drugs which were launched last year began to make contributions. The Company launched Tenelia, for the treatment of type2 diabetes mellitus, in September 2012. As a result, the domestic sales of ethical drugs were ¥176.6 billion, up 0.5%, year-on-year.
Overseas sales of ethical drugs increased 11.1%, year-on-year, to ¥10.1 billion, and sales of OTC products decreased 2.7%, year-on-year, to ¥2.8 billion.
Sales of others in pharmaceuticals increased 45.1%, year-on-year, to ¥11.1 billion due to the increase in royalty revenue from Gilenya, for the treatment of multiple sclerosis, licensed to Novartis.
In others, net sales were down 37.4%, or ¥1.8 billion, year-on-year, due to the transfer of fne chemical operations in July, 2012.

The Principal Products and Businesses in Each Business Segment
Pharmaceuticals: Ethical drugs, over-the-counter-drugs
Other businesses: Fine chemicals, real-estate leasing, information services, advertising, etc

[Billion yen]

Operating Income	32.2	Y-on-Y	(3.8)	(10.6 %)

Operating income decreased 10.6%, or ¥3.8 billion, year-on-year, to ¥32.2 billion.
Although net sales increased ¥3.4 billion, year-on-year, gross profit decreased ¥1.3 billion, year-on-year, to ¥124.5 billion due to the influence of NHI drug price revisions and other factors.. The cost of sales ratio worsened by 1.7 percentage points.
SG&A expenses increased ¥2.4 billion, year-on-year, to \92.3 billion, due to the increase in R&D expenses and the increase in sales expenses with the amortization of distribution rights for new products launched last year. R&D expenses were ¥34.2 billion, accounting for 16.8% of net sales.

[Billion yen]

Ordinary Income	33.1	Y-on-Y	(3.2)	(8.9 %)
Net Income	19.4	Y-on-Y	(0.4)	(2.4 %)

Ordinary income was down 8.9%, or ¥3.2 billion, year-on-year, to ¥33.1 billion, and net income was down 2.4%, or ¥0.4 billion, year-on-year, to ¥19.4 billion.
Extraordinary income was ¥1.2 billion, including gain on sales of property, plant and equipment.
Extraordinary losses were ¥3.6 billion, including loss on business integration of the plasma fractionation operations of ¥2.2 billion, and loss on valuation of investment in securities of ¥0.7 billion. In the previous fiscal year, the Company recorded extraordinary losses of ¥3.2 billion, such as loss on impairment of fixed assets.

2. Summary of Forecasts for FY2012

[Billion yen]

Net Sales	425.0	Y-on-Y	17.8	4.4 %
Operating Income	70.0	Y-on-Y	0.9	1.4 %
Ordinary Income	71.0	Y-on-Y	2.2	3.3 %
Net Income	40.5	Y-on-Y	1.4	3.8 %

3. Dividends

	FY2012 (Estimate)		FY2011	
	End of 1st Half	For the Year	End of 1st Half	For the Year
Dividends per Share (¥)	20	40	15	35
Dividends Payout Ratio	-	44.4%	-	40.0%

Note: The dividend payout ratio is calculated using net income (less amortization of goodwill) and dividends.

2 Consolidated Financial Indicators for 2nd Quater of FY2012

(Amounts less than ¥100 million are rounded down.)

1. Profit and Loss

(1) Profit and Loss

[Billion yen]

	1st Half of FY2012	Y-on-Y			Comparison to Forecasts		
		1st Half of FY2011	Increase (Decrease)	Change %	Forecast*1	Increase (Decrease)	Change %
Net sales	**203.8**	200.3	3.4	1.7	203.0	0.8	0.4
Cost of sales	**79.2**	74.4	4.8	6.5	76.5	2.7	3.6
Sales cost ratio	**38.9%**	37.2%			37.7%		
Gross operation profit	**124.5**	125.9	(1.3)	(1.1)	126.5	(1.9)	(1.5)
SG&A expenses	**92.3**	89.8	2.4	2.7	98.5	(6.1)	(6.3)
% of net sales	**45.3%**	44.9%			48.5%		
Operating income	**32.2**	36.0	(3.8)	(10.6)	28.0	4.2	15.2
Ordinary income	**33.1**	36.3	(3.2)	(8.9)	28.0	5.1	18.3
Extraordinary income	**1.2**	-	1.2	-	-	1.2	-
Extraordinary loss	**3.6**	3.2	0.3	-	3.5	0.1	4.1
Net income	**19.4**	19.9	(0.4)	(2.4)	15.0	4.4	29.9

(2) Sales by Business Segments

[Billion yen]

	1st Half of FY2012	Y-on-Y			Comparison to Forecasts			Notes [Y-on-Y Comparison]
		1st Half of FY2011	Increase (Decrease)	Change %	Forecast*1	Increase (Decrease)	Change %	
Pharmaceuticals	**200.7**	195.4	5.3	2.7	199.5	1.2	0.6	Ethical drugs domestic sales 0.9 Ethical drugs overseas sales 1.0 Contracted manufacturing products (1.0) Licensing fee, etc. 4.4 See page 5, "Sales of Main Products"
% Composition	**98.5%**	97.5%			98.3%			
Domestic	**183.3**	183.5	(0.2)	(0.1)	184.0	(0.6)	(0.3)	
Overseas	**17.3**	11.8	5.5	46.7	15.5	1.8	12.1	
Others	**3.0**	4.9	(1.8)	(37.4)	3.5	(0.4)	(11.6)	Decrease according to transfer of fine chemical operations
% Composition	**1.5%**	2.5%			1.7%			
Domestic	**2.0**	3.5	(1.5)	(43.4)	2.0	0.0	1.8	
Overseas	**1.0**	1.3	(0.2)	(21.6)	1.5	(0.4)	(29.5)	
Total	**203.8**	200.3	3.4	1.7	203.0	0.8	0.4	Overseas sales ratio 1st half of FY2011: 6.6% 1st half of FY2012: 9.0% Average exchange rate 1st half of FY2011, 1$= ¥81.78 1st half of FY2012, 1$= ¥79.78
% Composition	**100.0%**	100.0%			100.0%			
Domestic	**185.3**	187.1	(1.7)	(0.9)	186.0	(0.6)	(0.3)	
Overseas	**18.4**	13.1	5.2	39.7	17.0	1.4	8.4	

(3) Cost of Sales and Selling, General and Administrative Expenses

[Billion yen]

	1st Half of FY2012	Y-on-Y			Comparison to Forecasts			Notes [Y-on-Y Comparison]
		1st Half of FY2011	Increase (Decrease)	Change %	Forecast*1	Increase (Decrease)	Change %	
Cost of sales	**79.2**	74.4	4.8	6.5	76.5	2.7	3.6	The sales cost ratio is worsened due to the drug price revision, etc.
% of Net sales	**38.9%**	37.2%			37.7%			
SG&A expenses	**92.3**	89.8	2.4	2.7	98.5	(6.1)	(6.3)	
% of Net sales	**45.3%**	44.9%			48.5%			
R&D expenses	**34.2**	33.5	0.6	2.0	38.0	(3.7)	(9.9)	Increase according to the progress of the development pipeline in Japan, etc.
% of Net sales	**16.8%**	16.8%			18.7%			
Except R&D expenses	**58.0**	56.3	1.7	3.2	60.5	(2.4)	(4.0)	
Labor cost	**25.9**	25.9	0.0	0.2	26.0	0.0	(0.1)	
Amortization of goodwill*2	**5.0**	5.0	0.0	(0.1)	5.0	0.0	1.3	
Others	**27.0**	25.3	1.7	6.8	29.5	(2.4)	(8.3)	Increase in amortization of selling rights, etc.
Total labor cost	**45.0**	44.4	0.6	1.5	46.0	(0.9)	(2.0)	

*1: Published forecasts announced on May 8, 2012 in the financial results of FY2011

*2: Clear off 150.5 billion yen within 15 years.

(4) Non-operating Income and Loss

[Billion yen]

	1st Half of FY2012	1st Half of FY2011	Increase (Decrease)	Notes
Non-operating income	**2.3**	2.0	0.3	
Interest income	**0.8**	0.7	0.0	
Dividend income	**0.4**	0.4	0.0	
Equity in earnings of income	**0.4**	0.1	0.2	
Others	**0.6**	0.6	0.0	
Non-operating expenses	**1.4**	1.7	(0.2)	
Foreign exchange loss	**0.2**	0.4	(0.1)	
Donations	**0.2**	0.1	0.0	
Others	**0.9**	1.0	(0.1)	

(5) Extraordinary Income and Loss

[Billion yen]

	1st Half of FY2012	1st Half of FY2011	Increase (Decrease)	Notes
Extraordinary income	**1.2**	-	1.2	
Gains on sale of property, plant and equipment	**0.6**	-	0.6	
Gains on transfer of business	**0.3**	-	0.3	Gain on transfer of fine chemical operations
Gains on sale of investments in securities	**0.2**	-	0.2	
Extraordinary Loss	**3.6**	3.2	0.3	
Loss on business integration	**2.2**	-	2.2	Loss according to integration of plasma fracnation operations
Loss on valuation of investment in securities	**0.7**	0.0	0.6	
Impairment loss	**0.3**	2.9	(2.6)	1st half of FY2012: Nabari No.2 training center, etc. 1st half of FY2011: Sanban-cho office, Tokyo
Loss on sale of investments in securities	**0.1**	-	0.1	Choseido Pharmaceutical
Others	**0.2**	0.3	0.0	

(6) Taxes

[Billion yen]

	1st Half of FY2012	1st Half of FY2011	Increase (Decrease)
Income before income taxes and minority interests	**30.6**	33.0	(2.4)
Income taxes-current	**13.4**	10.4	3.0
Income taxes-deferred	**(2.3)**	2.5	(4.9)
Minority interests	**0.0**	0.1	0.0
Net Income	**19.4**	19.9	(0.4)

Notes

	1st Half of FY2012	1st half of FY2011
Statutory tax rate	37.9%	40.6%
Adjustment		
Non-deductible expenses	1.3%	2.4%
Non-taxable dividend income, etc.	(3.2%)	(3.1%)
Adjustment for per capital inhabitants tax	0.4%	0.2%
Special deduction for R&D expenses	(5.8%)	(9.4%)
Amortization of goodwill	6.2%	6.1%
Elimination of dividends upon consolidation	2.8%	2.8%
Others	(3.4%)	(0.4%)
Actual tax rate	36.2%	39.2%

(7) Sales of Main Products

[Billion yen]

	1st Half of FY2012	Y-on-Y			Comparison to Forecasts		
		1st Half of FY2011	Increase (Decrease)	Change %	Forecasts *1	Increase (Decrease)	Change %
Ethical drugs	**197.9**	192.5	5.3	2.8	196.5	1.4	0.7
Ethical drugs domestic sales	**176.6**	175.6	0.9	0.5	177.5	(0.8)	(0.5)
Remicade	**36.7**	32.0	4.6	14.6	37.0	(0.2)	(0.8)
Ceredist	**9.5**	8.9	0.6	6.7	9.0	0.5	5.9
Talion	**5.2**	5.3	0.0	(0.7)	6.0	(0.7)	(12.1)
Maintate	**6.9**	6.5	0.3	5.8	7.0	0.0	(0.4)
Radicut	**6.9**	12.7	(5.8)	(45.4)	8.0	(1.0)	(12.8)
Anplag	**6.8**	7.7	(0.9)	(11.7)	7.0	(0.1)	(2.7)
Urso	**6.7**	7.2	(0.4)	(6.2)	7.0	(0.2)	(3.4)
Kremezin	**6.0**	6.1	(0.1)	(2.9)	6.0	0.0	0.1
Venoglobulin IH	**5.5**	5.0	0.4	9.9	5.5	0.0	0.8
Depas	**5.2**	5.4	(0.1)	(2.8)	5.5	(0.2)	(3.8)
Telavic	**3.4**	-	3.4	-	3.5	0.0	(0.9)
Herbesser	**3.9**	4.3	(0.4)	(10.7)	4.0	0.0	(2.2)
Tanatril	**3.6**	4.2	(0.5)	(13.6)	3.5	0.1	5.6
Lexapro	**1.6**	0.4	1.2	279.7	2.0	(0.3)	(16.9)
Simponi	**2.2**	0.0	2.1	-	2.0	0.2	11.4
Liple	**2.6**	3.1	(0.5)	(16.7)	2.5	0.1	4.4
Neuart	**2.2**	2.5	(0.3)	(12.8)	2.5	(0.2)	(10.5)
BIKEN Products [Vaccine]	**12.6**	15.1	(2.5)	(16.5)	13.0	(0.3)	(2.9)
Mearubik	**5.4**	6.2	(0.8)	(13.7)	6.0	(0.5)	(9.7)
Influenza	**1.5**	2.3	(0.8)	(34.3)	2.0	(0.4)	(23.3)
JEBIK V	**3.5**	4.8	(1.3)	(27.1)	3.5	0.0	2.1
Tanabe Seiyaku Hanbai Products *2	**9.0**	8.2	0.8	10.6	8.5	0.5	6.8
Ethical drugs overseas sales	**10.1**	9.1	1.0	11.1	9.5	0.6	7.0
Herbesser	**2.3**	2.2	0.0	0.2	2.5	(0.1)	(8.0)
Argatroban (Novastan)	**1.3**	1.6	(0.2)	(15.5)	1.0	0.3	39.0
Tanatril	**0.8**	0.8	0.0	(0.7)	1.0	(0.1)	(13.5)
Vaccine	**1.0**	0.9	0.0	8.5	1.0	0.0	1.1
Contracted manufacturing products *3	**3.7**	4.7	(1.0)	(21.1)	3.5	0.2	7.8
Lincensing Fee, etc.	**7.3**	2.9	4.4	154.2	6.0	1.3	22.9
OTC products	**2.8**	2.8	0.0	(2.7)	3.0	(0.1)	(6.4)
Total Pharmaceuticals	**200.7**	195.4	5.3	2.7	199.5	1.2	0.6

*1: Published forecasts announced on May 8, 2012 in the financial results for FY2011.

*2: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*3: Active pharmaceutical ingredients and others ordered by other companies.

2. Financial Statement

(1) Balance Sheet

[Billion Yen]

	End of Q2 FY201 2	Composition %	End of FY2011	Increase (Decrease)	Notes
Total Aseets	**837.3**	**100.0**	819.9	17.3	
Current Assets	**444.3**	**53.1**	419.6	24.6	
Cash and deposits	**15.2**	**1.8**	15.4	(0.2)	See Page 7, (2) Cash Flows Statement
Marketable securities	**62.6**	**7.5**	46.3	16.2	Increase in negotiable deposits and government bond, etc
Notes and accounts receivable*1	**127.9**	**15.3**	127.2	0.7	
[Months/Revolution]	**[3.77]**		[3.75]	[0.02]	
Inventories	**93.5**	**11.2**	86.1	7.3	Increase in products, such as Remicade
Deposits	**131.1**	**15.7**	130.7	0.3	
Deferred income taxes	**9.7**	**1.2**	9.3	0.3	
Others	**4.0**	**0.5**	4.3	(0.3)	
Fixed Assets	**392.9**	**46.9**	400.2	(7.2)	
Property, plant and equipment	**102.0**	**12.2**	103.9	(1.8)	Investment for plant and equipment, 4.2; Depreciation, (3.7)
Intangible fixed assets	**108.9**	**13.0**	109.3	(0.4)	Investment for information system, 1.0; Goodwill accompanied with the aquisition of Bipha stocks, 4.2; Amortization of goodwill, (5.0); Depreciation, (0.5)
Investment in securities	**115.0**	**13.7**	116.5	(1.5)	Increase in corporate bond, decrease in government bond, decrease due to the transfer of Choseido Pharmaceutical stocks
Prepaid pension expenses	**39.7**	**4.8**	42.1	(2.3)	
Deferred income taxes	**9.4**	**1.1**	7.8	1.5	
Other investments	**17.7**	**2.1**	20.3	(2.6)	Decrease in long-term prepaid expense, etc.
Total Liabilities	**108.6**	**13.0**	98.4	10.1	
Current Liabilities	**81.5**	**9.7**	69.5	11.9	
Notes and accounts payable*2	**35.9**	**4.3**	28.8	7.0	Increase in debts for Remicade and vaccine, etc
Short-term debt	**0.7**	**0.1**	2.1	(1.4)	
Accrued payable	**16.1**	**1.9**	15.7	0.4	
Income taxes payable	**13.2**	**1.6**	6.7	6.4	
Other current liabilities	**15.4**	**1.8**	16.0	(0.6)	
Long-term Liabilities	**27.0**	**3.2**	28.8	(1.7)	
Deferred income taxes	**9.0**	**1.1**	9.3	(0.3)	
Accrued retirement benefits for employees	**10.0**	**1.2**	10.5	(0.5)	
Reserve for health management allowances for HIV compensation	**1.4**	**0.2**	1.4	-	
Reserve for health management allowances for SMON compensation	**3.3**	**0.4**	3.6	(0.2)	
Reserve for HCV litigation	**1.8**	**0.2**	2.5	(0.6)	Reversal accompanied with payment of the settlement
Other long-term liabilities	**1.3**	**0.2**	1.3	0.0	
Net Assets	**728.7**	**87.0**	721.4	7.2	
Shareholders' equity	**733.1**	**87.6**	724.8	8.2	
Common stock	**50.0**	**6.0**	50.0	-	
Capital surplus	**451.1**	**53.9**	451.1	-	
Retained earnings	**232.4**	**27.8**	224.1	8.2	Net income, 19.4; Payment for dividends, (11.2)
Teasury stock, at cost	**(0.4)**	**(0.1)**	(0.4)	-	
Accumulated other comprehensive loss	**(8.6)**	**(1.0)**	(9.1)	0.4	
Unrealized holding (losses) gains on securities	**0.5**	**0.1**	0.0	0.6	
Deffered (losses) gains on hedges	**(0.3)**	**(0.0)**	0.0	(0.4)	
Translation adjustments	**(8.9)**	**(1.1)**	(9.1)	0.2	
Minority interests	**4.2**	**0.5**	5.7	(1.4)	

*1: Note and accounts receivable = Bills + Accounts receivable

*2: Note and account payable=Bills(except non-operating bills)+Accounts payable

(2) Cash Flow Statement

[Billion yen]

	1st Half of FY2012	1st Half of FY2011	Increase (Decrease)	FY2011
Cash and cash equivalents at beginning of year	**54.3**	97.8	(43.5)	97.8
Cash flows from operating activities	**33.2**	16.3	16.8	37.2
Income before income taxes and minority interests	**30.6**	33.0	(2.4)	63.7
Depreciation and amortization	**4.3**	5.8	(1.4)	12.4
Loss on Impairment of fixed assets	**0.3**	2.9	(2.6)	3.3
Amortization of goodwill	**5.0**	5.0	0.0	10.1
Increase (decrease) in accrued retirement benefit for employees	**(0.5)**	(0.6)	0.0	(1.2)
Decrease (increase) in prepaid pension expenses	**2.3**	(0.8)	3.1	(1.6)
Increase (decease) in reserve for HCV litigation	**(0.6)**	(1.7)	1.0	(2.1)
Interest and dividend income	**(1.2)**	(1.1)	0.0	(2.3)
Loss (gain) on sales and disposal of fixed assets	**(0.5)**	0.0	(0.6)	(0.5)
Loss (gain) on transfer of business	**(0.3)**	-	(0.3)	-
Loss (gain) on valuation of investments in securities	**0.7**	0.0	0.6	2.1
Equity in (earning) losses of affiliates	**(0.4)**	(0.1)	(0.2)	(0.1)
Loss on business integration	**2.2**	-	2.2	-
Decrease(increase) in notes and accounts receivable, trade	**(0.7)**	0.9	(1.7)	0.9
Decrease (increase) in inventories	**(10.3)**	(6.1)	(4.1)	(8.6)
Increase (decrease) in notes and accounts payable, trade	**7.1**	2.7	4.3	(0.5)
Increase(decrease) in accounts patable, other	**(0.1)**	(3.6)	3.5	(2.1)
Interest and dividends received	**1.3**	1.2	0.0	2.5
Income taxes paid	**(7.0)**	(15.2)	8.2	(28.3)
Other, net	**1.2**	(6.0)	7.2	(10.4)
Cash flows from investing activities	**(19.0)**	(44.5)	25.5	(63.2)
Purchase/sales etc. of marketable securities	**(10.5)**	28.7	(39.2)	43.1
Increase/decrease in time deposits	**0.5**	8.8	(8.2)	9.3
Increase in deposits	**(0.3)**	(76.5)	76.1	(110.7)
Increase/decrease in long-term deposits	**-**	(0.4)	0.4	(0.4)
Purchase/sales of property, plant and equipment	**(1.1)**	(6.0)	4.9	(7.3)
Purchase of intangible fixed assets	**(0.9)**	(0.4)	(0.5)	(1.2)
Purchase/sales of investment in securities	**(2.1)**	1.2	(3.4)	4.0
Purchase/sales of investment in securities	**(5.8)**	-	(5.8)	-
Purchase of investments in subsidiaries	**1.3**	-	1.3	-
Other, net	**0.0**	0.0	0.0	0.0
Cash flows from financing activities	**(12.6)**	(8.6)	(3.9)	(17.1)
Increase (decrease) in short-term debt, net	**(1.4)**	(0.7)	(0.6)	(0.7)
Cash dividends paid	**(11.2)**	(7.8)	(3.3)	(16.2)
Other, net	**0.0**	0.0	0.0	(0.1)
Effect of exchange rate change on cash and cash equivalents	**0.0**	0.0	0.0	(0.3)
Net increase (decrease) in cash and cash equivalents	**1.5**	(36.7)	38.3	(43.5)
Cash and cash equivalents at end of the period	**55.9**	61.1	(5.1)	54.3

The Reconciliation of Cash and Cash Equivalents in the Consolidated Balance Sheets and Cash and Cash Equivalents in the Consolidated Statements of Cash Flows at the End of the Period [Billion yen]

	1st Half of FY2012	1st Half of FY2011	FY2011
Cash and time deposits	15.2	15.7	15.4
Time deposits maturing after three months	(1.9)	(2.7)	(2.4)
Short-term investments in marketable securities maturing within three months of acquisition	22.4	27.9	21.1
Cash and cash equivalents included in short-term loans receivable*	0.1	0.1	0.1
Cash and cash equivalents included in deposits	20.0	20.0	20.0
Cash and cash equivalents in the consolidated statements of cash flows	55.9	61.1	54.3

*: Short-term loans are included in "Others, Current Assets" on "2-(1) Balance Sheet" (page 6).

(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems

[Billion yen]

	1st Half of FY2012	1st Half of FY2011	Increase (Decrease)	FY2011
Investment in property, plant and equipment /occuring basis	4.2	2.8	1.4	7.0
Investment in information systems/occuring basis	1.0	0.3	0.6	1.2

Major investment in property, plant and equipment in 1st half of FY2012		Major investment in development of imformation sysytems in 1st half of FY2012	
Mitsubishi Tanabe Pharma	2.0	Mitsubishi Tanabe Pharma	0.9
[Electric generator at Toda office]	[0.3]		
[Related to transfer of Tokyo head office]	[0.3]		
Mitsubishi Tanabe Pharma Factory	1.3		
Benesis	0.4		

(4) Depreciation Costs

[Billion yen]

	1st Half of FY2012	1st Half of FY2011	Increase (Decrease)	FY2011
Property, plant and equipment	3.7	5.3	(1.5)	11.4
Intangible fixed assets	0.5	0.5	0.0	1.0

3. Financial Data & Employee Numbers of Major Consolidated Subsidiaries

	Companies	Benesis Corporation	Mitsubishi Tanabe Pharma Factory Ltd.	Tanabe Seiyaku Hanbai Co., Ltd	Mitsubishi Tanabe Pharma Korea Co., Ltd.	Mitsubishi Pharma (Guangzhou) Co., Ltd.	Tianjin Tanabe Seiyaku Co., Ltd.
	Fiscal Year	End of Mar.	End of Mar.	End of Mar.	End of Dec.	End of Dec.	End of Dec.
Net Sales	1st Half of FY2012	**8.4**	**26.1**	**9.0**	**1.6**	**0.2**	**1.1**
	FY2011	19.5	54.8	17.4	3.6	0.1	2.1
	1st Half of FY2011	10.9	27.3	8.2	1.8	0.0	1.0
Operating Income	1st Half of FY2012	**(0.4)**	**1.7**	**0.4**	**0.1**	**(0.4)**	**0.0**
	FY2011	2.5	3.2	1.1	0.2	(0.9)	0.0
	1st Half of FY2011	2.1	1.7	0.4	0.2	(0.5)	0.0
Ordinary Income	1st Half of FY2012	**(0.5)**	**1.6**	**0.4**	**0.1**	**(0.4)**	**0.0**
	FY2011	2.7	3.4	1.1	0.2	(1.0)	0.0
	1st Half of FY2011	2.1	1.9	0.4	0.2	(0.5)	0.0
Net Income and Loss	1st Half of FY2012	**(2.0)**	**1.1**	**0.1**	**0.1**	**(0.4)**	**0.0**
	FY2011	1.5	1.8	1.1	0.1	(1.0)	0.0
	1st Half of FY2011	1.3	1.1	0.5	0.1	(0.5)	0.0
R&D Expenses	1st Half of FY2012	**1.0**	**0.5**	**-**	**-**	**0.0**	**-**
	FY2011	1.8	0.9	-	-	0.0	0.0
	1st Half of FY2011	0.9	0.4	-	-	0.0	-
Depreciation of Property, Plant and Equipment	1st Half of FY2012	**0.6**	**0.9**	**-**	**0.0**	**0.0**	**0.0**
	FY2011	1.1	3.6	0.0	0.0	0.0	0.0
	1st Half of FY2011	0.5	1.6	0.0	0.0	0.0	0.0
Total Assets	1st Half of FY2012	**27.6**	**63.6**	**7.3**	**2.1**	**3.1**	**1.9**
	FY2011	32.0	58.4	7.4	2.1	2.9	1.8
	1st Half of FY2011	31.7	57.4	6.0	2.4	3.2	2.0
Net Assets	1st Half of FY2012	**23.3**	**39.5**	**0.1**	**1.6**	**1.8**	**1.4**
	FY2011	26.1	39.3	0.0	1.5	2.2	1.3
	1st Half of FY2011	25.9	38.6	(0.5)	1.7	2.7	1.4
Number of Employees	1st Half of FY2012	**55.6**	**133.2**	**16.6**	**12.2**	**46.3**	**42.2**
	FY2011	56.5	123.8	16.6	12.5	42.5	39.2
	1st Half of FY2011	56.7	125.0	16.7	12.5	39.5	37.5

3 Forecasts for FY2012 Ending March 31, 2013

(Amounts less than ¥100 million are rounded down.)

(1) Consolidated Forecasts of Profit and Loss

[Billion yen]

	2nd Half of FY2012 Forecasts	2nd Half of FY2011 Actual	Increase (Decrease)	Change %	FY2012 Forecasts*	FY2011 Actual	Increase (Decrease)	Change %	Notes
Net Sales	**221.1**	206.7	14.3	7.0	**425.0**	407.1	17.8	4.4	
Cost of Sales	**87.7**	77.8	9.8	12.7	**167.0**	152.2	14.7	9.7	
Sales cost ratio	**39.7%**	37.6%			**39.3%**	37.4%			
Gross Operatin Profit	**133.4**	128.9	4.4	3.5	**258.0**	254.8	3.1	1.2	
SG & A Expenses	**95.6**	95.9	(0.2)	(0.3)	**188.0**	185.8	2.1	1.2	
% of Net Sales	**43.3%**	46.4%			**44.2%**	45.6%			
Operating Income	**37.7**	32.9	4.7	14.4	**70.0**	69.0	0.9	1.4	
Ordinary Income	**37.8**	32.3	5.4	17.0	**71.0**	68.7	2.2	3.3	
Extraordinary Income or los	**(2.5)**	(1.6)	(0.8)	-	**(5.0)**	(4.9)	0.0	-	
Net Income	**21.0**	19.0	1.9	10.3	**40.5**	39.0	1.4	3.8	

(2) Sales Forecasts by Segments

[Billion yen]

	2nd Half of FY2012 Forecasts	2nd Half of FY2011 Actual	Increase (Decrease)	Change %	FY2012 Forecasts	FY2011 Actual	Increase (Decrease)	Change %	Notes
Pharmaceuticals	**219.7**	202.1	17.6	8.7	**420.5**	397.5	22.9	5.8	
% Composition	**99.4%**	97.7%			**98.9%**	97.6%			
Domestic	**198.6**	188.2	10.3	5.5	**382.0**	371.8	10.1	2.7	
Overseas	**21.1**	13.8	7.2	52.5	**38.5**	25.6	12.8	49.8	
Other Businesses	**1.4**	4.6	(3.2)	(69.8)	**4.5**	9.5	(5.0)	(53.1)	
% Composition	**0.6%**	2.3%			**1.1%**	2.4%			
Domestic	**0.0**	3.3	(3.3)	-	**2.0**	6.9	(4.9)	(71.3)	
Overseas	**1.4**	1.2	0.1	12.2	**2.5**	2.6	(0.1)	(5.1)	
Total	**221.1**	206.7	14.3	7.0	**425.0**	407.1	17.8	4.4	Foreign sales ratio FY2011: 7.0% FY2012 estimation: 9.6%
% Composition	**100.0%**	100.0%			**100.0%**	100.0%			
Domestic	**198.6**	191.6	6.9	3.6	**384.0**	378.8	5.1	1.4	Exchange rate planned: 1US$=¥81
Overseas	**22.5**	15.1	7.4	49.1	**41.0**	28.3	12.6	44.7	

(3) Forecasts of Cost of Sales and SG&A Expenses

[Billion yen]

	2nd Half of FY2012 Forecasts	2nd Half of FY2011 Actual	Increase (Decrease)	Change %	FY2012 Forecasts	FY2011 Actual	Increase (Decrease)	Change %	Notes
Cost of Sales	**87.7**	77.8	9.8	12.7	**167.0**	152.2	14.7	9.7	The sales cost ratio is worsened due to the drug price revision.
Sales cost ratio	**39.7%**	37.6%			**39.3%**	37.4%			
SG & A Expenses	**95.6**	95.9	(0.2)	(0.3)	**188.0**	185.8	2.1	1.2	
% of Net sales	**43.3%**	46.4%			**44.2%**	45.6%			
R&D Expenses	**35.7**	36.6	(0.9)	(2.5)	**70.0**	70.2	(0.2)	(0.3)	
% of Net sales	**16.2%**	17.7%			**16.5%**	17.3%			
Except R&D Expenses	**59.9**	59.2	0.6	1.1	**118.0**	115.5	2.4	2.1	
Labor Cost	**25.5**	26.0	(0.5)	(1.9)	**51.5**	51.9	(0.4)	(0.9)	
Amortization of Goodwill *	**5.1**	5.0	0.0	1.4	**10.2**	10.1	0.0	0.7	
Others	**29.2**	28.1	1.0	3.8	**56.3**	53.4	2.8	5.2	Increase in amortization of selling right, etc.
Total Labor Cost	**43.9**	44.3	(0.4)	(1.0)	**89.0**	88.7	0.2	0.2	

*: Considering the financial results for 1st half of FY2012, the Company revised the forecast which was annouced on May 8 in the financial results for FY2011; in the revised forecast, net sales decrease from ¥429 billion to ¥425 billion, ordinary income increases from ¥70.0 to ¥71.0. See "Summary of 2nd Quater of Financial Results for year ended March 31, 2013 (Japan GAAD)" for the details.

(4) Sales Forecasts for Main Products [Billion yen]

	1st Half of FY2012 Forecasts	1st Half of FY2011 Actual	Increase (Decrease)	Change %	FY2012 Forecasts	FY2011 Actual	Increase (Decrease)	Change %
Ethical drugs	**217.0**	199.6	17.4	8.7	**415.0**	392.1	22.8	5.8
Ethical drugs domestic sales	**192.3**	179.7	12.6	7.0	**369.0**	355.4	13.5	3.8
Remicade	**38.2**	34.2	4.0	11.8	**75.0**	66.3	8.6	13.1
Ceredist	**9.4**	9.0	0.3	4.4	**19.0**	18.0	0.9	5.5
Talion	**9.7**	8.0	1.6	21.1	**15.0**	13.3	1.6	12.4
Maintate	**8.0**	7.1	0.9	13.1	**15.0**	13.6	1.3	9.6
Radicut	**7.0**	9.7	(2.6)	(27.6)	**14.0**	22.4	(8.4)	(37.8)
Anplag	**6.6**	7.5	(0.8)	(11.2)	**13.5**	15.2	(1.7)	(11.5)
Urso	**6.7**	7.2	(0.5)	(7.2)	**13.5**	14.4	(0.9)	(6.7)
Kremezin	**6.4**	5.4	1.0	18.8	**12.5**	11.6	0.8	7.3
Venoglobulin IH	**5.9**	5.6	0.3	5.5	**11.5**	10.6	0.8	7.5
Depas	**5.2**	5.5	(0.3)	(6.3)	**10.5**	10.9	(0.4)	(4.5)
Telavic	**5.0**	1.4	3.5	238	**8.5**	1.4	7.0	471.6
Herbesser	**3.5**	4.2	(0.6)	(16.0)	**7.5**	8.6	(1.1)	(13.3)
Tanatril	**3.3**	4.0	(0.7)	(18.6)	**7.0**	8.3	(1.3)	(16.1)
Lexapro	**3.8**	0.8	3.0	369.1	**5.5**	1.2	4.2	337.9
Simponi	**4.7**	0.9	3.8	427.4	**7.0**	0.9	6.0	634.5
Liple	**2.3**	3.0	(0.6)	(22.2)	**5.0**	6.2	(1.2)	(19.4)
Neuart	**2.2**	2.7	(0.5)	(19.1)	**4.5**	5.3	(0.8)	(16.1)
BIKEN Products [Vaccine]	**16.8**	13.6	3.1	23.4	**29.5**	28.8	0.6	2.4
Mearubik	**2.5**	3.2	(0.6)	(21.0)	**8.0**	9.5	(1.5)	(16.2)
Influenza	**6.9**	6.6	0.2	4.0	**8.5**	9.0	(0.5)	(5.9)
JEBIK V	**2.4**	2.2	0.1	8.2	**6.0**	7.1	(1.1)	(16.0)
Tanabe Seiyaku Hanbai Products *1	**9.9**	9.2	0.6	6.9	**19.0**	17.4	1.5	8.7
Ethical drugs overseas sales	**13.3**	9.3	4.0	43.2	**23.5**	18.4	5.0	27.3
Herbesser	**3.6**	2.5	1.1	43.8	**6.0**	4.8	1.1	23.2
Argatroban (Novastan)	**1.1**	1.4	(0.3)	(22.5)	**2.5**	3.0	(0.5)	(18.8)
Tanatril	**1.1**	0.8	0.3	35.9	**2.0**	1.7	0.2	17.2
Vaccine	**0.9**	0.6	0.3	52.2	**2.0**	1.5	0.4	26.4
Contracted manufacturing products *2	**3.2**	3.8	(0.6)	(17.1)	**7.0**	8.6	(1.6)	(19.3)
Lincensing Fee, etc.	**8.1**	6.6	1.4	21.4	**15.5**	9.5	5.9	61.5
OTC products	**2.6**	2.5	0.1	7.0	**5.5**	5.4	0.0	1.8
Total Pharmaceuticals	**219.7**	202.1	17.6	8.7	**420.5**	397.5	22.9	5.8

*1: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.
*2: Active pharmaceutical ingredients and others ordered by other compnies.

(5) Forecasts of Investment for Property, Plant and Equipment and Information Systems

[Billion yen]

	2nd Half of FY2012 Forecasts	2nd Half of FY2011 Actual	Increase (decrease)	Change %	FY2012 Forecasts	FY2011 Actual	Increase (decrease)	Change %
Investment in property, plant and equipment/occuring basis	6.3	4.2	2.0	48.0	10.5	7.0	3.4	48.8
Investment for information systems/occuring basis	1.0	0.8	0.1	18.9	2.0	1.2	0.8	66.1

[Billion yen]

Major investment in property, plant and equipment in 2nd half of FY2012		Major investment for information systems in 2nd half of FY2012	
Facilities & Equipment for R&D	2.7	R&D Related Systems	0.4
Production Facilities	2.3	Others	0.6
Others	1.3		

(6) Forecasts for Depreciation Costs

[Billion yen]

	2nd Half of FY2012 Forecasts	2nd Half of FY2011 Actual	Increase (decrease)	Change %	FY2012 Forecasts	FY2011 Actual	Increase (decrease)	Change %
Property, plant and equipment	3.7	6.1	(2.4)	(39.5)	7.4	11.4	(3.9)	(34.6)
Intangible fixed assets	0.6	0.5	0.0	14.9	1.1	1.0	0.1	15.1

4 Five-Year Financial Data

Amounts less than ¥100 million are rounded down.

(1) Profit and Loss

[Billion yen]

	FY2008	FY2009	FY2010	FY2011	1st half of FY2012	Forecast for FY2012
Net sales	414.7	404.7	409.5	407.1	203.8	425.0
Cost of sales	158.1	147.8	154.5	152.2	79.2	167.0
Gross operation profit	256.5	256.9	254.9	254.8	124.5	258.0
SG&A expenses	184.8	195.4	178.3	185.8	92.3	188.0
R&D expenses	73.1	83.0	65.7	70.2	34.2	70.0
Operating income	71.6	61.4	76.5	69.0	32.2	70.0
Ordinary income	72.5	61.6	76.6	68.7	33.1	71.0
Extraordinaly income	1.2	0.0	0.6	1.1	1.2	(5.0)
Extraordinaly loss	25.7	10.7	13.2	6.1	3.6	
Net income	26.5	30.2	37.7	39.0	19.4	40.5

(2) Balance Sheet

[Billion yen]

	End of FY2008	End of FY2009	End of FY2010	End of FY2011	End of 1st half of FY2012
Total assets	810.7	796.8	818.7	819.9	837.3
Current assets	364.4	344.2	391.5	419.6	444.3
Fixed assets	446.3	452.6	427.1	400.2	392.9
Total liabilities	144.5	120.0	122.7	98.4	108.6
Current liabilities	89.1	77.7	87.7	69.5	81.5
Fixed liabilities	55.3	42.2	35.0	28.8	27.0
Net assets	666.2	676.8	695.9	721.4	728.7

(3) Other Financial Data

[Billion yen]

	FY2008	FY2009	FY2010	FY2011	1st half of FY2012	Forecast for FY2012
Cash flows from operating activities	50.5	23.9	59.0	37.2	33.2	-
Cash flows from investing activities	(74.5)	(61.2)	(7.6)	(63.2)	(19.0)	-
Cash flows from financing activities	(15.9)	(17.1)	(15.4)	(17.1)	(12.6)	-
Investments in property, plant and equipment	12.1	8.3	10.1	7.0	4.2	10.5
Investments for development of information systems	1.7	0.8	0.8	1.2	1.0	2.0
Depreciation costs	15.6	13.2	12.4	12.4	4.3	8.6
Equity ratio (%)	80.5	84.1	84.3	87.3	86.5	-
ROE (%)	4.1	4.6	5.5	5.5	5.4	-
Net income per share (¥)	47.28	53.91	67.27	69.54	34.75	72.19
Net assets per share (¥)	1,162.69	1,194.79	1,230.16	1,275.85	1,291.38	-

(4) Number of Employees

	End of FY2008	End of FY2009	End of FY2010	End of FY2011	End of 1st half of FY2012	Forecast for End of FY2012
Consolidated	10,030	9,266	9,198	9,180	9,427	8,900
Non-consolodated	5,715	5,186	4,957	4,826	4,893	4,820

5 Quaterly Trend

(Amounts less than ¥100 million are rounded down.)

(1) Profit and Loss

[Billion yen]

	FY2011					FY2012		
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	FY2011 Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Forecast for FY2012
Net sales	102.2	98.1	115.3	91.4	407.1	104.3	99.4	425.0
	25.1%	24.1%	28.3%	22.5%	100.0%	24.6%	23.4%	100.0%
Domestic	95.7	91.4	108.0	83.6	378.8	95.6	89.7	384.0
	25.3%	24.1%	28.5%	22.1%	100.0%	24.9%	23.4%	100.0%
Overseas	6.5	6.6	7.3	7.7	28.3	8.7	9.6	41.0
	23.1%	23.5%	25.9%	27.5%	100.0%	21.4%	23.5%	100.0%
Pharmaceuticals	99.7	95.6	112.9	89.2	397.5	101.9	98.8	420.5
	25.1%	24.1%	28.4%	22.4%	100.0%	24.2%	23.5%	100.0%
Domestic	93.7	89.8	106.2	82.0	371.8	93.7	89.6	382.0
	25.2%	24.2%	28.6%	22.1%	100.0%	24.5%	23.5%	100.0%
Overseas	6.0	5.8	6.6	7.1	25.6	8.2	9.1	38.5
	23.4%	22.7%	26.0%	27.8%	100.0%	21.4%	23.8%	100.0%
Others	2.5	2.4	2.4	2.1	9.5	2.4	0.6	4.5
	26.1%	25.4%	25.7%	22.8%	100.0%	54.8%	13.9%	100.0%
Domestic	1.9	1.6	1.8	1.5	6.9	1.8	0.1	2.0
	28.3%	23.4%	26.0%	22.4%	100.0%	95.0%	6.8%	100.0%
Overseas	0.5	0.8	0.6	0.6	2.6	0.5	0.4	2.5
	20.3%	30.9%	24.9%	23.9%	100.0%	22.7%	19.6%	100.0%
Cost of sales	37.3	37.0	44.8	32.9	152.2	40.6	38.6	167.0
Sales Cost Ratio	36.5%	37.8%	38.9%	36.1%	37.4%	38.9%	38.8%	39.3%
Gross operating profit	64.8	61.0	70.5	58.4	254.8	63.7	60.8	258.0
	25.5%	23.9%	27.7%	22.9%	100.0%	24.7%	23.6%	100.0%
SG&A expenses	42.1	47.7	46.6	49.3	185.8	44.9	47.4	188.0
	22.7%	25.7%	25.1%	26.6%	100.0%	23.9%	25.2%	100.0%
R&D expenses	15.7	17.8	18.0	18.6	70.2	16.9	17.3	70.0
	22.4%	25.4%	25.7%	26.5%	100.0%	24.2%	24.7%	100.0%
Non-R&D expenses	26.4	29.8	28.5	30.7	115.5	27.9	30.0	118.0
	22.9%	25.9%	24.7%	26.6%	100.0%	23.7%	25.5%	100.0%
Labor costs	12.6	13.3	12.9	13.1	51.9	12.9	13.0	51.5
	24.3%	25.6%	24.9%	25.2%	100.0%	25.1%	25.3%	100.0%
Amortization of goodwill	2.5	2.5	2.5	2.5	10.1	2.5	2.5	10.2
	25.0%	25.0%	25.0%	25.0%	100.0%	24.8%	24.8%	100.0%
Others	11.2	14.0	13.0	15.0	53.4	12.5	14.5	56.3
	21.1%	26.3%	24.5%	28.2%	100.0%	22.3%	25.8%	100.0%
Operating income	22.7	13.3	23.8	9.1	69.0	18.8	13.4	70.0
	32.9%	19.3%	34.6%	13.2%	100.0%	26.9%	19.2%	100.0%
Ordinary income	22.9	13.3	24.0	8.3	68.7	19.6	13.4	71.0
	33.4%	19.5%	34.9%	12.2%	100.0%	27.7%	19.0%	100.0%
Net income	11.4	8.5	15.8	3.1	39.0	10.8	8.6	40.5
	29.3%	21.9%	40.7%	8.1%	100.0%	26.7%	21.4%	100.0%

The each figure (excluding Cost of sales) in the lower displays the progress rate.

(2) Sales of Main Products

[Billion yen]

	FY2011					FY2012		
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	FY2010 Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Forecast for FY2012
Ethical drugs	98.3	94.2	111.4	88.1	392.1	100.5	97.3	415.0
	25.1%	24.0%	28.4%	22.5%	100.0%	24.2%	23.5%	100.0%
Ethical drugs domestic sales	89.7	85.9	102.8	76.8	355.4	90.5	86.1	369.0
	25.3%	24.2%	28.9%	21.6%	100.0%	24.5%	23.3%	100.0%
Remicade	15.8	16.2	18.9	15.3	66.3	17.9	18.7	75.0
	23.9%	24.5%	28.5%	23.1%	100.0%	23.9%	25.0%	100.0%
Ceredist	4.6	4.2	5.1	3.9	18.0	5.0	4.5	19.0
	25.9%	23.7%	28.4%	22.0%	100.0%	26.3%	23.8%	100.0%
Talion	3.0	2.2	3.9	4.1	13.3	3.0	2.2	15.0
	22.9%	16.9%	29.3%	30.9%	100.0%	20.3%	14.8%	100.0%
Maintate	3.4	3.1	4.0	3.0	13.6	3.6	3.3	15.0
	24.9%	23.3%	29.6%	22.3%	100.0%	24.2%	22.2%	100.0%
Radicut	6.7	6.0	5.9	3.7	22.4	3.7	3.2	14.0
	29.9%	26.9%	26.4%	16.7%	100.0%	26.5%	23.3%	100.0%
Anplag	4.0	3.6	4.4	3.0	15.2	3.6	3.1	13.5
	26.8%	23.7%	29.4%	20.1%	100.0%	27.1%	23.3%	100.0%
Urso	3.7	3.4	4.1	3.0	14.4	3.4	3.2	13.5
	26.2%	23.6%	28.9%	21.3%	100.0%	25.9%	24.2%	100.0%
Kremezin	2.8	3.3	2.8	2.5	11.6	3.1	2.8	12.5
	24.4%	28.6%	24.8%	22.1%	100.0%	25.1%	23.0%	100.0%
Venoglubulin IH	2.4	2.5	3.2	2.3	10.6	2.8	2.6	11.5
	23.3%	23.8%	30.6%	22.2%	100.0%	24.9%	23.3%	100.0%
Depas	2.8	2.6	3.1	2.4	10.9	2.7	2.5	10.5
	25.5%	24.0%	28.3%	22.2%	100.0%	26.3%	24.1%	100.0%
Telavic	-	-	0.1	1.3	1.4	2.1	1.3	8.5
	-	-	12.0%	88.0%	100.0%	25.3%	15.5%	100.0%
Herbesser	2.3	2.0	2.4	1.7	8.6	2.1	1.8	7.5
	27.0%	23.6%	28.8%	20.6%	100.0%	28.1%	24.0%	100.0%
Tanatril	2.2	2.0	2.3	1.6	8.3	1.9	1.7	7.0
	27.3%	24.0%	28.6%	20.1%	100.0%	28.1%	24.7%	100.0%
Lexapro	-	0.4	0.3	0.4	1.2	0.7	0.9	5.5
	-	34.9%	28.0%	37.1%	100.0%	13.7%	16.6%	100.0%
Simponi	-	0.0	0.3	0.5	0.9	1.0	1.1	7.0
	-	5.0%	38.4%	56.6%	100.0%	14.9%	16.9%	100.0%
Liple	1.6	1.4	1.7	1.3	6.2	1.4	1.2	5.0
	26.6%	23.9%	28.1%	21.4%	100.0%	28.0%	24.2%	100.0%
Neuart	1.2	1.2	1.6	1.1	5.3	1.1	1.0	4.5
	23.9%	23.9%	31.6%	20.6%	100.0%	25.9%	23.8%	100.0%
BIKEN products [Vaccine]	7.0	8.0	9.4	4.2	28.8	6.1	6.5	29.5
	24.4%	28.0%	32.7%	14.8%	100.0%	20.7%	22.0%	100.0%
Mearubik	4.1	2.1	1.1	2.0	9.5	3.3	2.0	8.0
	43.6%	22.2%	12.3%	21.9%	100.0%	42.1%	25.7%	100.0%
Influenza	0.0	2.3	6.4	0.2	9.0	0.0	1.5	8.5
	(0.1%)	26.0%	71.2%	3.0%	100.0%	(0.5%)	18.5%	100.0%
JEBIK V	2.0	2.8	1.2	0.9	7.1	1.7	1.7	6.0
	29.3%	39.3%	18.0%	13.4%	100.0%	29.8%	29.8%	100.0%
Tanabe Seiyaku Hanbai products *1	4.3	3.8	5.2	4.0	17.4	4.8	4.2	19.0
	24.9%	22.0%	29.8%	23.3%	100.0%	25.5%	22.3%	100.0%
Ethical drugs overseas sales	4.6	4.4	4.7	4.6	18.4	4.5	5.6	23.5
	25.3%	24.2%	25.5%	24.9%	100.0%	19.4%	23.9%	100.0%
Herbesser	1.1	1.0	1.3	1.2	4.8	1.1	1.1	6.0
	24.6%	22.5%	27.1%	25.7%	100.0%	19.1%	19.3%	100.0%
Argatroban (Novastan)	0.9	0.6	0.7	0.6	3.0	0.7	0.6	2.5
	32.3%	21.1%	25.6%	21.0%	100.0%	28.6%	27.0%	100.0%
Tanatril	0.3	0.4	0.4	0.3	1.7	0.4	0.4	2.0
	22.9%	28.2%	27.7%	21.3%	100.0%	22.5%	20.8%	100.0%
Vaccine	0.4	0.4	0.3	0.3	1.5	0.2	0.7	2.0
	29.8%	29.1%	21.0%	20.0%	100.0%	13.7%	36.9%	100.0%
Contracted manufacturing products *2	2.4	2.3	1.7	2.1	8.6	1.7	2.0	7.0
	28.3%	26.9%	20.2%	24.6%	100.0%	24.6%	29.3%	100.0%
Lincensing fee, etc.	1.4	1.4	2.0	4.5	9.5	3.7	3.5	15.5
	15.0%	15.2%	21.9%	47.9%	100.0%	24.4%	23.2%	100.0%
OTC products	1.4	1.4	1.4	1.0	5.4	1.3	1.4	5.5
	26.4%	27.0%	27.3%	19.3%	100.0%	24.7%	26.4%	100.0%
Total pharmaceuticals	99.7	95.6	112.9	89.2	397.5	101.9	98.8	420.5
	25.1%	24.1%	28.4%	22.4%	100.0%	24.2%	23.5%	100.0%

The each figure in the lower displays the progress rate.

*1: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*2: Active pharmaceutical ingredients and products ordered by other companies.

6 State of New Product Development (As of Oct. 29, 2012)

1. Pipeline in Japan

(1) New Molecular Entities

Development code (Generic name)	Category (Indications)	Stage	Origin
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	Phase 3	In-house
MP-214 (Cariprazine)	D3/D2 receptor partial agonist (Schizophrenia)	Phase 2b/3	Hungary: Gedeon-Richter
MP-435	C5a receptor antagonist (Rheumatoid arthritis)	Phase 2	In-house
MT-4666	α7nACh receptor agonist (Alzheimer's disease)	Phase 1	US: EnVivo
MT-3995	Selective mineralocorticoid receptor antagonist (Hypertention)	Phase 1	In-house
MT-1303	Sphingosine-1-phosphate receptor functional antagonist (Multiple sclerosis)	Phase 1	In-house

(2) Additional Indications

Product name (Generic name)	Category (Indications)	Stage	Origin
Omeprazon (Omeprazole)	Proton pump inhibitor (Hericobacter pylori eradication by concomitant therapy for Hericobacter pylori gastritis)	sNDA filed	UK:AstraZeneca
Maintate (Bisoprolol)	Selective β 1 blocker (Chronic atrial fibrillation)	sNDA filed	Switzerland: Merck Serono
Grtpa (Alteplase[recombinant])	Thrombolytic agent (Acute ischemic cerebrovascular disease [up to 4.5 hours after the onset of symptoms])	sNDA filed	US:Genentech
Radicut (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis*)	Phase 3	In-house
Talion (Bepotastine)	Selective histamine H1 receptor antagonist, anti-allergic agent (Pediatric allergic rhinitis)	Phase 3	Japan: Ube Industries
Telavic (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C, [genotype2])	Phase 3	US:Vertex
Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus, additional combination)	Phase 3	In-house
Remicade (Infliximab [recombinant])	Anti- human TNFα monoclonal antibody (Refractory Kawasaki disease*)	Phase 3	US:Janssen Biotech
	(Behcet's disease with special lesions*)	Phase 3	
	(Pediatric Crohn's disease)	Phase 3	
	(Pediatric ulcerative colitis)	Phase 3	
	(Psoriasis: increased dose)	Phase 3	
Cholebine (Colestimide[JAN])	Bile acid signal regulation (Type 2 diabetes mellitus)	Phase 2	In-house
	Non-absorbed phosphate binder (Hyperphosphatemia)	Phase 1	

* Orphan drug designated

2. Pipelines Overseas

(1) New Molecular Entities

Development code/ Product name(Generic name)	Category (Indications)	Region	Stage	Origin
MCI-196/BindRen (Colestilan[INN])	Non-absorbed phosphate binder (Hyperphosphatemia)	Europe	MAA filed (Aug. 2011)	In-house
MP-146	Uremic toxin adsorbent (Chronic kidney disease)	US, Europe	Phase 3	Japan:Kureha
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Europe	Phase 2	In-house
		US	Phase 1	
GB-1057 (Recombinant human serum albumin)	Recombinant human serum albumin (Stabilizing agent)	US	Phase 1	In-house
MP-124	PARP inhibitor (Acute ischemic stroke)	US, Canada	Phase 1	In-house
MT-3995	Selective mineralocorticoid receptor antagonist (Hypertention)	Europe	Phase 1	In-house
MP-157	Angiotensin Type 2 receptor agonist (Hypertention)	Europe	Phase 1	In-house
MT-1303	Sphingosine-1-phosphate receptor functional antagonist (Multiple sclerosis)	Europe	Phase 1	In-house
MT-7716	NOP receptor agonist (Alcohol-use disorder)	US	Phase 1	In-house

3. Licensing-out

Development code (Generic name)	Category (Indications)	Region	Stage	Licensee
TA-1790 (Avanafil)	PDE5 inhibitor (Erectile dysfunction)	Europe	MAA filed (Mar. 2012)	US: Vivus
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type2 diabetes mellitus)	US	NDA filed (May 2012)	US: Janssen Pharmaceuticals
		Europe	MAA filed (Jun. 2012)	
	(Obesity)	US, Europe	Phase 2	
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Korea	Phase 3	Korea: Handok
T-0047 (Firategrast)	Cell adhesion inhibitor [α4β7/α4β1 inhibitor] (Multiple sclerosis)	Europe	Phase 2	UK: GlaxoSmithKline
MKC-242	5-HT1A receptor agonist (Insomnia)	US	Phase 2	US: MediciNova
Y-39983	ROCK (rho-kinase) inhibitor (Glaucoma)	Japan	Phase 2	Japan: Senju Pharmaceutical
MT-210	5-HT2A/ Sigma 2 receptor antagonist (Schizophrenia)	Europe	Phase 2	France: Cyrenaic
TA-7906	PDE4 inhibitor (Atopic dermatitis)	Japan	Phase 2	Japan: Maruho
sTU-199 (Tenatoprazole)	Proton pump inhibitor (Gastroesophageal reflux disease)	Europe	Phase 1	France: Negma (Sidem)
TT-138	β3 receptor agonist (Pollakiuria, urinary incontinence)	US	Phase 1	US: MediciNova

4. Changes Since Previous Announcement on July 31, 2012

(1) In-house Development

Development code/Product name (Generic name)	Category (Indications)	Region	As of July 31, 2012	As of October 29, 2012
Omeprazon (Omeprazole)	Proton pump inhibitors (Hericobacter pylori eradication by concomitant therapy for Hericobacter pylori	Japan	None	Filed (August 2012)
Maintate (Bisoprolol)	Selective β 1 blocker (Chronic atrial fibrillation)	Japan	Phase 3	Filed (September 2012)
Grtpa (Alteplase[recombinant])	Thrombolytic agents (Acute ischemic cerebrovascular disease [up to 4.5 hours after the onset of symptoms])	Japan	None	Filed (September 2012)
Remicade (Infliximab [recombinant])	Anti- human TNFα monoclonal antibody (Psoriasis: increased dose)	Japan	None	Phase 3
TA-8995	CETP inhibitor (Dyslipidemia)	EU	Phase 1	Discontinued
Venoglobulin IH (Polyethylene glycol treated human normal immunoglobulin)	Human immunoglobulin G (IgG2 deficiency)	Japan	Filed	Deleted *
	(Systemic scleroderma)	Japan	Phase 3	

* Due to the transfer of plasma fractionation operations

(2) Licensing-out

Development code (Generic name)	Category (Indications)	Region	As of July 31, 2012	As of October 29, 2012
TA-7906	PDE4 inhibitor (Atopic dermatitis)	Japan	Phase 1	Phase 2

5. Additional Information for State of New Product Development (as of October 29, 2012)

(1) New Molecular Entities in Japan

Development code (Generic name)	Information
TA-7284 (Canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsportion of glucose in the kidney. Clinical stage is Phase 3 for type2 diabetes mellitus.
MP-214 (Cariprazine)	MP-214 is a dopamine D3/D2 receptor partial agonist, licensed from Gedeon-Richter (Hungary). Clinical stage is Phase 2b/3 for schizophrenia.
MP-435	MP-435 is an oral C5a (complement factor) receptor antagonist which modulates the immune system. Clinical stage is Phase 2 for Rheumatoid arthritis.
MT-4666	MT-4666 is an α7 nACh receptor agonist, licensed from EnVivo pharmaceuticals(US). Clinical stage is Phase 1.
MT-3995	MT-3995 is a selective mineralocorticoid receptor antagonist. Clinical stage is Phase 1.
MT-1303	MT-1303 is a sphingosine-1-phosphate receptor functional antagonist. Clinical stage is Phase1 as a succesor of Imusera/Gilenya.

(2) Additional Indications in Japan

Product name (Generic name)	Information
Omeprazon (Omeprazole)	(Hericobacter pylori eradication by concomitant therapy for Hericobacter pylori gastritis) Omeprazon is a proton pump inhibitor. It was launched as a treatment for gastric, duodenal and stoma ulcers, reflux esophagitis and zollinger-ellison syndrome in 1991. An additional indications for Hericobacter pylori eradication by concomitant therapy were approved. sNDA has been filed for Hericobacter pylori gastritis of Hericobacter pylori eradication by concomitant therapy, responding the request from the academic society.
Maintate (Bisoprolol)	(Chronic atrial fibrillation) Maintate is a selective β1 antagonist. It is launched as a treatment for hypertension, angina and premature ventricular beat in 1990. An additional indication for heart failure was approved in 2011. sNDA has been filed for chronic atrial fibrillation with data of clinical trial, responding the request from the academic society.
Grtpa (Alteplase[recombinant])	(Acute ischemic cerebrovascular disease [up to 4.5 hours after the onset of symptoms]) Grtpa was launched as a thrombolytic agent for Acute myocardial infarction in 1991. An additional indication for improvement of the functional disability in the acute ischemic cerebrovascular disease(up to 3 hour after the onset of symptoms) was approved in 2005. Publicknowledge-based sNDA has been filed for an extention from 3 hours after the onset of symptoms to 4.5 hours for Grtpa for injection, responding the request from the academic society.
Radicut (Edaravone)	(Amyotrophic lateral sclerosis [Orphan drug designated in June, 2005]) Radicut is a free radical scavenger. In 2001, it was launched for improvement neurological symptoms at the acute stage of cerebral infarction, interference with activities of daily living and functional disability. Clinical stage is Phase 3.
Talion (Bepotastine)	(Pediatric allergic rhinitis) We launched this drug as an anti-allergic agent for adult in 2000. Clinical stage is Phase 3.
Telavic (Telaprevir)	(Chronic hepatitis C [genotype2]) It was launched as a treatment for chronic hepatitis C in 2011. Clinical stage is Phase 3.
Tenelia (Teneligliptin)	Tenelia is developed for the treatment of type2 diabetes mellitus. It selectively inhibits dipeptidyl peptidase 4 (DPP-4), thus accelerates the insulin secretion after meal intake without effect on the fasting insulin secretion. It was launched in September, 2012. Additional combination trial is on going.
Remicade (Infliximab[recombinant])	Remicade is an anti-human TNFα monoclonal antibody. This was launched as a treatment for Crohn's disease in 2002, followed by as a treatment for rheumatoid arthritis, intractable uveoretinitis caused by Behcet's disease, psoriasis, ankylosing spondylitis, and ulcerative colitis. (Refractory Kawasaki disease [Orphan drug designated in September, 2012]) Clinical stage is Phase 3.
	(Behcet's disease with special lesions [Orphan drug designated in September, 2012]) Clinical stage is Phase 3.
	(Pediatric Crohn's disease) Clinical stage is Phase 3.
	(Pediatric ulcerative colitis) Clinical stage is Phase 3.
	(Psoriasis: inceased dose) Clinical stage is Phase 3.
Cholebine (Colestimide[JAN])	Cholebine is a bile acid eliminant. It was launched as a treatment for hypercholesterolemia in 1999. (Type 2 diabetes mellitus) Clinical stage is Phase 2.
	(Hyperphosphatemia) Clinical stage is Phase 1.

(3) New Molecular Entities in Overseas

Development code/Product name (Generic name)	Information
MCI-196 / BindRen (Colestilan[INN])	MCI-196 has been developed for the treatment of hyperphosphatemia in patients on dialysis. MAA has been filed in August 2011, and EMA adopted a positive opinion for the marketing authorisation in September 2012 in Europe. It has been marketed in Japan for the treatment of hypercholesterolemia, under the brand name of CHOLEBINE®.
MP-146	MP-146 is spherical carbon adsorbent, licensed from KUREHA (Japan) in November 2006. Clinical stage is Phase 3 for chronic kidney disease patients in Europe, North America and Latin America. It had been marketed by Daiichi Sankyo in Japan from 1991 under the brand name, KREMEZIN®. In April 2011, Mitsubishi Tanabe Pharma succeeded its marketing from Daiichi Sankyo.
MP-513 (Teneligliptin)	MP-513 is developed for the treatment of type2 diabetes mellitus. It selectively inhibits dipeptidyl peptidase 4 (DPP-4), thus accelerates the insulin secretion after meal intake without effect on the fasting insulin secretion. Clinical stages in the US and Europe are Phase 1 and Phase 2, respectively.
GB-1057 (Recombinant human serum albumin)	GB-1057 is a recombinant human serum albumin. Clinical stage is Phase 1 as a stabilizing agent in the US.
MP-124	MP-124 is a PARP inhibitor that has neuroprotective effect. Clinical stage in the US and Canada are Phase 1.
MT-3995	MT-3995 is a selective mineralocorticoid receptor antagonist. Clinical stage is Phase 1 in Europe.
MP-157	MP-157 is an angiotensin type2 receptor agonist. Clinical stage is Phase 1 in Europe.
MT-1303	MT-1303 is a sphingosine-1-phosphate receptor functional antagonist. Clinical stage is Phase 1 as a succesor of Imusera/Gilenya.
MT-7716	MT-7716 is an NOP receptor agonist. Clinical stage is Phase 1 in the US.

(4) Licensing-out

Development code (Generic name)	Information
TA-1790 (Avanafil)	TA-1790 is created for the treatment of erectile dysfunction which is expected to have a quick onset and fewer side effects. In Europe, MAA was filed by Vivus in March 2012. In the US, Vivus obtained NDA approval in April 2012.
TA-7284 (Canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsorption of glucose in the kidney. NDA, in the US in May, and MAA, in Europe in June, were submitted by Janssen Pharmaceuticals, Inc. Phase 2 clinical trials in obesity in Europe and the US are completed.
MP-513 (Teneligliptin)	MP-513 selectively inhibits dipeptidyl peptidase 4 (DPP-4), thus accelerates the insulin secretion after meal intake without effect on the fasting insulin secretion. Phase 3 trial is conducting by Handok in Korea.
T-0047 (Firategrast)	T-0047 inhibits the cell adhesion and cell migration processes of white blood cells in inflammatory region. Phase 2 trial is conducted by GSK in Europe, etc.
MKC-242	MKC-242 is a serotonin 1A receptor agonist, used to treat psychiatric disorders such as anxiety and depression. This compound is expected to express rapid onset with low possibility of dependency. Medici Nova (US) is conducting Phase 2 clinical trial for insomnia.
Y-39983	Y-39983 is a ROCK (Rho-kinase) inhibitor, which relaxes vascular smooth muscle. Clinical stage is Phase 2 in Japan by Senju Pharmaceutical.
MT-210	MP-210 is a 5-HT2A/ Sigma 2 receptor antagonist. Clinical stage is Phase 2 in Europe by Cyrenaic (France).
TA-7906	TA-7906 is a PDE4 inhibitor. Clinical stage is Phase 2 for the treatment of atopic dermatitis in Japan by Maruho.
sTU-199 (Tenatoprazole)	sTU-199 is an isomer of TU-199, developed in Japan, and licensed to Negma (France). Pharmacokinetic/pharmacodynamic results from Phase 1 clinical trials in Europe and the US demonstrated that sTU-199 controlled gastric acid secretion at nighttime in patients receiving this compound once-daily, with the long half-life. It is expected that this compound could reveal rapid improvement for non-erosive reflux disease. Sidem Pharma, a subsidiary of Negma, is conducting phase 1 study in Europe.
TT-138	TT-138 is a β3 receptor agonist used to treat pollakiuria and urinary incontinence. Phase 1 study is conducted by MediciNova in the US.

7 Others

1 Subsidiaries and Affiliated Companies

(1) Number of Subsidiaries and Affiliated Companies

	End of 1st Half of FY2012	End of FY2011	Increase (Decrease)	Notes
Consolidated subsidiaries	**28**	28	-	
Non-consolidated subsidiaries	**1**	3	-2	Decrease: Choseido Pharmaceutical, Hoshienu Pharmaceutical
Affiliated companies	**5**	3	2	Increase: Choseido Pharmaceutical, Hoshienu Pharmaceutical
Total	**34**	34	-	

(2) Consolidated Subsidiaries [As of September 30, 2012]

	Company Name	Paid-in Capital (Million yen)	% Voting Control [% Indirect Ownership]		Settling Day	Description of Business
1	Benesis Corporation	3,000	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
2	Mitsubishi Tanabe Pharma Factory Ltd.	1,130	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
3	Mitsubishi Tanabe Pharma Korea Co., Ltd.	KRW 2,100,000,000	100.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
4	Mitsubishi Pharma (Guangzhou) Co., Ltd.	US$12,000,000	100.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
5	Tianjin Tanabe Seiyaku Co., Ltd.	US$12,000,000	66.7	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
6	Yoshitomiyakuhin Corporation	385	100.0	[-]	End of Mar.	Provision of information about pharmaceuticals
7	MP-Logistics Corporation	95	65.0	[-]	End of Mar.	Distribution, warehouse operations
8	BIPHA CORPORATION	7,500	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
9	Tanabe Seiyaku Yoshiki Factory Co., Ltd.	400	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
10	Tanabe Seiyaku Hanbai., Ltd.	169	90.6	[5.6]	End of Mar.	Sale of generic pharmaceuticals and related products
11	Tanabe R&D Service Co., Ltd.	44	100.0	[-]	End of Mar.	Support of R&D regarding pharmaceuticals
12	Tanabe Total Service Co., Ltd.	90	100.0	[-]	End of Mar.	Real estate management and etc.
13	MP Healthcare Venture Management, Inc.	US$100	65.0	[-]	End of Dec.	Investments in bio-ventures
14	Mitsubishi Tanabe Pharma Holdings America, Inc.	US$166	100.0	[-]	End of Dec.	Management of group companies in US
15	Mitsubishi Tanabe Pharma Development America, Inc.	US$100	100.0	[100.0]	End of Dec.	R&D of pharmaceuticals
16	Tanabe Research Laboratories U.S.A., Inc.	US$3,000,000	100.0	[100.0]	End of Dec.	R&D of pharmaceuticals
17	Tanabe U.S.A., Inc.	US$1,400,000	100.0	[100.0]	End of Dec.	Sale of chemicals
18	Mitsubishi Tanabe Pharma America, Inc.	US$100	100.0	[100.0]	End of Dec.	Sale of pharmaceuticals
19	Mitsubishi Pharma Research & Development (Beijing) Co., Ltd.	US$1,000,000	100.0	[-]	End of Dec.	R&D of pharmaceuticals
20	Guangdong Tanabe Pharmaceutical Co., Ltd.	CNY 7,000,000	100.0	[-]	End of Dec.	Sale of pharmaceuticals
21	Taiwan Tanabe Seiyaku Co., Ltd.	NT$90,000,000	65.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
22	Tai Tien Pharmaceuticals Co., Ltd.	NT$20,000,000	65.0	[-]	End of Dec.	Sale of pharmaceuticals
23	P.T. Tanabe Indonesia	US$2,500,000	99.6	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
24	Mitsubishi Pharma Europe Ltd.	£4,632,000	100.0	[-]	End of Dec.	R&D of pharmaceuticals
25	Mitsubishi Pharma Deutschland GmbH	EUR 25,000	100.0	[100.0]	End of Dec.	Sale of pharmaceuticals
26	Tanabe Europe N.V.	EUR 260,330	100.0	[-]	End of Dec.	Sale of chemicals

Note: Aside from the companies mentioned above, there are two consolidated companies under the liquidations.

(3) Affiliated Companies Accounted for by the Equity Method [As of September 30, 2012]

	Company Name	Paid-in Capital (Million yen)	% Voting Control [% Indirect Ownership]		Settling Day	Description of Business
1	Choseido Pharmaceutical Co.,Ltd.	340	37.1	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
2	Hoshienu Pharmaceutical Co.,Ltd.	75	24.1	[24.1]	End of Mar.	Manufacture and sale of pharmaceuticals
1	API Corporation	4,000	47.7	[-]	End of Mar.	Manufacture and sale of API
2	Synthelabo-Tanabe Chimie S.A.	EUR 1,600,000	50.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals

2 Status of Shareholders

(1) Number of Outstanding Shares

	The End of September, 2012	The End of March, 2012
Issued	**561,417,916**	561,417,916
The company's own shares at the end of the period	**423,681**	423,532
Number of shares outstanding at the end of the period	**560,994,235**	560,994,384
Average number of the company's own share in the period	**423,611**	364,350
Average number of shares outstanding in the period	**560,994,305**	561,053,566

(2) Status of Major Shareholders

Rank	Name of Shareholders	The End of September, 2012		The End of March, 2012		
		Number of Shares (Thousands)	Percentage of Total	Rank	Number of Shares (Thousands)	Percentage of Total
1	Mitsubishi Chemical Holdings Corporation	316,320	56.34%	1	316,320	56.34%
2	Japan Trustee Services Bank, Ltd.	35,220	6.27%	2	32,566	5.80%
3	The Master Trust of Japan, Ltd.	29,692	5.29%	3	28,150	5.01%
4	Nippon Life Insurance Company	15,112	2.69%	4	15,137	2.70%
5	Nipro Corporation	7,642	1.36%	5	7,642	1.36%
6	The Bank of Tokyo-Mitsubishi UFJ, Ltd.	7,254	1.29%	6	7,254	1.29%
7	JP Morgan Chase Bank, N.A., 385147	7,100	1.26%	7	7,100	1.26%
8	Trust & Custody Services Bank, Ltd.	5,012	0.89%	11	4,051	0.72%
9	Goldman Sachs & Company Regular Account	4,903	0.87%	9	4,297	0.77%
10	Employee Stock Ownership Plan	4,567	0.81%	8	4,423	0.79%

(3) Ownership and Distribution of Shares

	The End of September, 2012			The End of March, 2012		
	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total
Financial institutions	73	112,250	20.00%	64	106,350	18.95%
Foreign corporations and others	383	78,576	14.00%	375	82,524	14.70%
Individuals and others *	13,371	26,648	4.75%	13,850	27,518	4.90%
Other corporations	277	342,713	61.06%	282	342,629	61.04%
Securities firms	33	1,120	0.20%	57	2,285	0.41%
Total	14,137	561,309	100.00%	14,628	561,308	100.00%
Less than trading unit	-	108	-	-	109	-

The trading unit of the Company's stock is 100 shares.

* Individuals and Others include treasury stock (423 thousands shares at the end of September, 2012 and 423 thousands shares at the end of March, 2012)

(4) Trend of Divinded and Stock Price

	FY2008	FY2009	FY2010	FY2011	1st Half of FY2012	FY2012 Estimate
Dividends per share (yen)	28	28	28	35	20	40
Dividend payout ratio(%)	59.2	51.9	41.6	50.3	-	55.4
(prior to amortization of goodwill)	(43.0)	(39.0)	(32.9)	(40.0)	(-)	(44.4)
Stock price at the end of FY	971	1320	1350	1161	1187	-
Market capitalization (billion yen)	5,451	7,410	7,579	6,518	6,664	-

Reference

Major Ethical Drugs

Remicade (Infliximab)	Launch: May 2002	Category	Anti-TNFα monoclonal antibody
Remicade is an anti-TNFα antibody, which targets TNFα, an important inflammatory cytokine. It is very fast-acting and its efficacy is sustained for eight weeks with a single administration. It has indications for the treatment of rheumatoid arthritis, Crohn's disease, Behcet's disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, and ulcerative colitis. In addtion, in July 2009 and August 2011, changes in usage/dosage were approved for rheumatoid arthritis, and Crohn's disease, respectively. Origin: Jannsen Biotech			
Ceredist (Taltirelin)	Launch: Sep. 2000	Category	Agent for treatment of spinocerebellar degeneration
Thyrotropin releasing hormone (TRH) was known to be effective against ataxia caused by spinocerebellar degeneration, but it was previously administered only through injection. Ceredist, developed by Tanabe, is the world's first oral TRH derivative drug. An additional formulation, orally disintegrating tablets, was launched in October 2009.			
Talion (Bepotastine)	Launch: Oct. 2000	Category	Agent for treatment of allergic disorders
Talion has rapid onset of anti-histamine(H1) effects and has been demonstrated to be effective for allergic rhinitis, urticaria, and pruritus accompanying dermatitis. It has minimal incidence of sedation. An additional formulation, orally disintegrating tablets, was approved in March and launched in July 2007. Origin: Ube Industries			
Maintate (Bisoprolol)	Launch: Nov. 1990	Category	Selective β1 antagonist (Treatment of hypertension, angina pectoris, and arrhythmias)
Maintate is a representative β-blocker used in more than 85 countries around the world. It exhibits high selectivity for β1 receptor and excellent phamacokinetics profiles. It has high efficacy and safety, and there is evidence for its cardioprotective action. An additional indication for chronic heart failure has been approved in May, 2011. Origin: Merck Serono			
Radicut (Edaravone)	Launch: Jun. 2001	Category	Free radical scavenger (Cerebral neuroprotectant)
Radicut is the world's first brain protecting agent (free radical scavemger) shown to improve neurological symptoms, interference with activities of daily living, and disability (at hospital discharge) in patients at acute stage of cerebral infarction. Specific indications include the treatment of various types of infarction (cerebral lacunar, atherothrombotic and cardiogenic infarction) It is initiated administration within 24 hours after onset, and is not administrated for more than 14 days. An additional formulation, Radicut bag for I.V. Infusion, was launched in May 2010.			
Anplag (Sarpogrelate)	Launch: Oct. 1993	Category	5-HT2 blocker (Anti-platelet agent)
Anplag, an oral anti-platelet, is used to patients with arteriosclerosis obliterans (ASO) to improve ischemic symptoms like as ulcer, pain and coldness of limbs associated with chronic arterial occlusion. Anplag especially improves the bloodstream of collateral circulation and inhibits platelet aggregation, vascular contraction and growth of vascular smooth muscle cell by antagonistic action to serotonin receptor in platelets and vessels.			
Urso (Ursodeoxycholic Acid)	Launch: July 1962	Category	Agent for improving hepatic, biliary and digestive functions
Ursodeoxycholic acid (UDCA), principal ingredient of Urso, had been extracted from blackbear's gallbladder in the past and has been used in the treatment of various digestive diseases. It is one of the bile acids existing in the human body. Urso has effects of hapatic protection and indications of improvement of liver function in chronic liver disease and hepatitis C, and dissolution of gallstones.			
Kremezin	Launch: Apr. 2011	Category	Agent for treatment of Chronic renal failure
Kremezin is an oral absorptive charcoal consisting of porous spherical activated carbon of high purity. It absorbs and excretes uremic toxins out of the body. Keremezin was introduced to the Japanese market in December 1991 as the first pharmaceuticals drug in the world for proactive treatment of chronic renal failure (progressive). In April, 2011, the marketing rights were transferred from Daiichi Sankyo to MTPC. Origin, Manufacturer and distributor: Kureha			
Venoglobulin IH (Human immunoglobulin)	Launch: Jan. 1992	Category	Plasma derivatives
Venoglobulin IH is intravenous human immunoglobulin derived from donated plasma in Japan. It shows high efficacy on serious infectious diseases in combined administration with an anti-bacterial agent due to its opsonic, immuno-bacteriolytic and antibody-dependent cytotoxic effects and neutralizing effects on toxics and viruses. In October 2010 and September 2011, the indications for improvement of muscle weakness associated with polymyositis or dermatomyositis and generalized myasthenia gravis (only in case of insufficient response to steroids or immunosuppressants) were added, respectively. It is expected to be a new treatment option for the diseases that contribute better QOL for patients.			
Depas (Etizolam)	Launch: Mar. 1984	Category	Antianxiety agent
Depas is the most widely used anxiolytic agent in Japan. Due to its broad pharmacological properties, Depas shows reasonable effectiveness for psychosomatic disease, neurosis, low back pain, neck pain and muscle-contraction headache, depression and sleep disorder.			

Telavic (Telaprevir)	Launch: Nov. 2011	Category	NS3-4A protease inhibitor
Teravic is positioned in the first-in-class oral drug for treating chronic hepatitis C. It inhibits hepatitis C virus (HCV) proliferation by inhibiting NS3-4A protease which involved in HCV replication. It was revealed that the combination therapy of three drugs (pegylated interferon, ribavirin and Teravic) improves therapeutic efficacy and shortens the treatment period, compared to the current standard therapy, for the patients with chronic hepatitis C affected by genotype 1 virus. In addition, it is expected to offer the new treatment opportunity to patients for whom the conventional treatment was not effective. Origin: Vertex			
Herbesser (Diltiazem)	Launch: Feb. 1974	Category	Calcium antagonist (Treatment of angina pectoris and hypertension)
Herbesser is a representative calcium antagonist that is used in more than 110 countries around the world. In addition to a blood pressure lowering effect, it has a cardioprotective action in patients with hypertension or angina pectoris by reducing the cardiac load through a heart rate lowering effect and by increasing the oxygen supply through a coronary vasodilating effect.			
Tanatril (Imidapril)	Launch: Dec. 1993	Category	ACE inhibitor (Treatment of hypertension)
Tanatril shows excellent blood pressure control with effective organ protection as well as minimal incidence of dry cough, a common side effect of ACE inhibitors. With the approval of an additional indication in January 2002, it became the first drug in Japan approved for diabetic nephropathy with type I diabetes mellitus.			
Lexapro (Escitalopram)	Launch: Aug. 2011	Category	Selective sertonin reuptake inhibitor (SSRI)
Lexapro is a selective serotonin reuptake inhibitor with high selectivity of serotonin transporter, and available in more than 96 countries and regions. By having good efficacy and tolerability, in addition to simple administration, it is expected to contribute to the improvement of medication adherence for patients with depression. Origin: H. Lundbeck, Manufacturer and distributor: Mochida Pharmaceutical			
Simponi (Golimumab)	Launch: Sep. 2011	Category	Anti-TNFα monoclonal antibody
Simponi is a human anti-TNFα monoclonal antibody for the treatment of rheumatoid arthritis (including prevention of articular structural damage), and co-marketed with Janssen Pharmaceutical. It shows a long acting efficacy by subcutaneous injection once every four weeks, and currently is under development for the ulcerative colitis by Janssen Pharmaceutical. Origin: Janssen Biotech			
Liple (Arprostadil)	Launch: Nov. 1988	Category	Agent for treatment of Chronic arterial occlusion / Circulatory disturbance (PGE1)
Liple, the world's first DDS (Drug Delivery System) agent of intravenous PGE1, improves the peripheral circulatory disturbance and skin ulcer in chronic arterial occlusive disease and diabetes by its direct vasodilating effects. DDS maximizes the therapeutic effects and simultaneously minimizes the adverse effects of PGE1.			
Neuart (Anti-thrombin III)	Launch: Jun. 1987	Category	Plasma derivatives (Anticoagulant agent)
Neuart is highly purified human anti-thrombin III derived from donated plasma in Japan. It shows strong anticoagulant effects in the treatment of DIC patients by inhibiting various kinds of activated serine protease including thrombin.			
Mearubik (Live Attenuated Measles and Rubella Vaccine)	Launch: Dec. 2005	Category	Prevention of measles and rubella
Mearubik is the combination vaccine for measles and rubella, and children are able to receive both measles and rubella shot at a time with Mearubik. It is expected to contribute enhancement of immunization rate for measles and rubella in Japan. Origin, Manufacturer and distributor: BIKEN (The Research Foundation for Microbial Diseases of Osaka University)			
JEBIK V (Cell Culture-derived Japanese Encephalitis Vaccine)	Launch: Jan. 2009	Category	Prevention of Japanese encephalitis
JEBIK V is a freeze-dried preparation containing inactivated Japanese encephalitis virus derived from Vero cells which were used in the manufacturing process as a host to increase the virus. A freeze-dried prepared vaccine is available in routine vaccination. Accordingly, it is expected to increase in number of vaccinated persons. Origin, Manufacturer and distributor: BIKEN (The Research Foundation for Microbial Diseases of Osaka University)			

News Releases

The major news releases after April, 2012 are as follows.
Please refer to the Company's website for the details. (http://www.mt-pharma.co.jp/e/index.php)

Date	Contents
May 7, 2012	VIVUS gains NDA approval for TA-1790 in the US
May 8, 2012	Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody Lifting of Condition on Approval for Psoriasis
May 8, 2012	Remicade for I.V. Infusion 100, Anti-Human TNF α Monoclonal Antibody A New Option to Shorten Infusion Time
May 8, 2012	New Organization in Plasma Fractionation Operations Establishment of "Japan Blood Products Organization"
May 9, 2012	Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Indonesia
May 15, 2012	Notice Regarding Transfer of Fine Chemical Operations
June 1, 2012	Termination of License Agreement with Cytochroma for MT-2832 (Generic Name: Lunacalcipol) as a Treatment for Secondary Hyperparathyroidism
June 6, 2012	Launch of Pitavastatin Calcium, a Hypercholesterolemia Treatment Agent, in Taiwan
June 22, 2012	Launch of Generic Drugs *
June 29, 2012	Marketing and Manufacturing Approval Received for TENELIA 20mg Tablets A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan
July 6, 2012	Launch of Argatroban, a Selective Antithrombin Agent, in UK
July 23, 2012	Launch of Tranquilizer, DEPAS TABLETS 0.25 mg
August 28, 2012	Launch of TENELIA 20mg Tablets A DPP-4 Inhibitor for Type 2 Diabetes Mellitus Originating from Japan
August 31, 2012	Notice regarding dissolution of Bipha Corporation-related joint venture with Nipro Corporation
August 31, 2012	Companies Submit Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or Metronidazole
September 13, 2012	MAINTATE Tablets: Selective β1 Antagonist Notice regarding application for additional indication for chronic atrial fibrillation
September 20, 2012	Launch of "Simponi", a human TNFα monoclonal antibody in Indonesia
September 28, 2012	Application for time-window extension of the thrombolytic agents GRTPA and ACTIVACIN up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular disease
October 1, 2012	Outsourcing of Logistics Operations
October 10, 2012	Outcome of Global Phase III (EPPIC) Studies
October 19, 2012	Notice Regarding Dissolution of Capital Alliance with Choseido Pharmaceutical Co., Ltd.
October 26, 2012	Launch of TETRABIK Subcutaneous Injection Syringe An Adsorbed Purified Pertussis-Diphtheria-Tetanus Inactivated Polio (Sabin Strain) Combined Vaccine

*: Only in Japanese